

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 05-403	Serial No. To Be Assigned 10/536939
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)			
<b>Applicant:</b> Christophe Revirron			
<b>Filing Date:</b> Herewith		<b>Group:</b> To Be Assigned	

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	A1	WO 94/06429 A	March 31, 1994	PCT				x

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	A2	XP002240083, "Xyzal (Levocetirizine) launched in England for Allergic Rhinitis", 2001, <a href="http://www.psigroup.com/dg/207766.htm">www.psigroup.com/dg/207766.htm</a> .
	A3	XP002240084, "Germany Approves Antihistamines Xyzal", 2001, <a href="http://www.psigroup.com/dg/lefc66.htm">www.psigroup.com/dg/lefc66.htm</a> .
	A4	Gensthaler, B. M., "Levocetirizine: R-enantiomer against allergies", <i>Pharmazeutische Zeitung</i> , 2001, Vol. 146, No. 7, pp. 35-36.
	A5	Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.", <i>Annals of Allergy, Asthma &amp; Immunology: Official Publication of the American College of Allergy, Asthma, &amp; Immunology</i> , 2002, Vol. 88, No. 2, pp. 190-197.
	A6	Gandon et al., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.", <i>British Journal of Clinical Pharmacology</i> , 2002, Vol. 54, No. 1, pp. 51-58.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.